NewAmsterdam Pharma Company Ownership 2024 | Who Owns NewAmsterdam Pharma Company Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

100.00%

Insider Ownership

0.26%

Retail Ownership

-0.26%

Institutional Holders

20.00

NewAmsterdam Pharma Company Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	82.48%	9.09%	9,341,551	-	-	125,550,445,000	Mar 31, 2023
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC	73.29%	13.76%	8,300,000	-	-	110,058,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	35.32%	1.20%	4,000,000	-	-	53,040,000,000	Mar 31, 2023
VIKING GLOBAL INVESTORS LP	34.58%	0.25%	3,915,870	162,042	4.32%	52,629,293,000	Mar 31, 2023
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	22.39%	0.75%	2,535,723	55,524	2.24%	33,623,687,000	Mar 31, 2023
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD	17.66%	11.36%	2,000,000	-	-	26,520,000,000	Mar 31, 2023
BVF INC/IL	13.44%	0.75%	1,521,948	-	-	20,454,981,000	Mar 31, 2023
GMT CAPITAL CORP	9.57%	0.56%	1,083,800	83,800	8.38%	14,371,188,000	Mar 31, 2023
ENSIGN PEAK ADVISORS, INC	3.13%	0.01%	355,000	-	-	4,707,300,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	2.55%	0.03%	289,265	289,265	100.00%	3,835,654,000	Mar 31, 2023
PARKMAN HEALTHCARE PARTNERS LLC	1.02%	0.33%	115,000	115,000	100.00%	1,524,900,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.49%	0.00%	55,633	55,633	100.00%	748,000	Mar 31, 2023
EVERSEPT PARTNERS, LP	0.40%	0.05%	45,856	45,856	100.00%	608,051,000	Mar 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	0.27%	0.00%	30,100	30,100	100.00%	399,126,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.20%	-	22,367	21,265	1929.67%	301,000,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.16%	-	18,559	18,559	100.00%	249,432,000	Mar 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.	0.06%	0.00%	6,533	6,533	100.00%	12,000	Mar 31, 2023
WOLVERINE ASSET MANAGEMENT LLC	0.04%	0.00%	4,819	4,819	100.00%	63,899,000	Mar 31, 2023
MORGAN STANLEY	0.00%	-	503	503	100.00%	6,670,000	Mar 31, 2023
ATTICUS WEALTH MANAGEMENT, LLC	0.00%	0.00%	166	166	100.00%	2,202,000	Mar 31, 2023

NewAmsterdam Pharma Company's largest institutional shareholder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 82.48% of the company's total share outstanding, currently valued at $125.55B. The top 10 institutional shareholders own together 294.41% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC	73.29%	13.76%	8,300,000	-	-	110,058,000	Mar 31, 2023
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD	17.66%	11.36%	2,000,000	-	-	26,520,000,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	82.48%	9.09%	9,341,551	-	-	125,550,445,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	35.32%	1.20%	4,000,000	-	-	53,040,000,000	Mar 31, 2023
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	22.39%	0.75%	2,535,723	55,524	2.24%	33,623,687,000	Mar 31, 2023
BVF INC/IL	13.44%	0.75%	1,521,948	-	-	20,454,981,000	Mar 31, 2023
GMT CAPITAL CORP	9.57%	0.56%	1,083,800	83,800	8.38%	14,371,188,000	Mar 31, 2023
PARKMAN HEALTHCARE PARTNERS LLC	1.02%	0.33%	115,000	115,000	100.00%	1,524,900,000	Mar 31, 2023
VIKING GLOBAL INVESTORS LP	34.58%	0.25%	3,915,870	162,042	4.32%	52,629,293,000	Mar 31, 2023
EVERSEPT PARTNERS, LP	0.40%	0.05%	45,856	45,856	100.00%	608,051,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	2.55%	0.03%	289,265	289,265	100.00%	3,835,654,000	Mar 31, 2023
ENSIGN PEAK ADVISORS, INC	3.13%	0.01%	355,000	-	-	4,707,300,000	Mar 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	0.27%	0.00%	30,100	30,100	100.00%	399,126,000	Mar 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.	0.06%	0.00%	6,533	6,533	100.00%	12,000	Mar 31, 2023
ATTICUS WEALTH MANAGEMENT, LLC	0.00%	0.00%	166	166	100.00%	2,202,000	Mar 31, 2023
WOLVERINE ASSET MANAGEMENT LLC	0.04%	0.00%	4,819	4,819	100.00%	63,899,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.49%	0.00%	55,633	55,633	100.00%	748,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.20%	-	22,367	21,265	1929.67%	301,000,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.16%	-	18,559	18,559	100.00%	249,432,000	Mar 31, 2023
MORGAN STANLEY	0.00%	-	503	503	100.00%	6,670,000	Mar 31, 2023

The largest NewAmsterdam Pharma Company shareholder by % of total assets is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC. The company owns 8.30M shares of NewAmsterdam Pharma Company (NAMS), representing 13.76% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ALYESKA INVESTMENT GROUP, L.P.	2.55%	0.03%	289,265	289,265	100.00%	3,835,654,000	Mar 31, 2023
VIKING GLOBAL INVESTORS LP	34.58%	0.25%	3,915,870	162,042	4.32%	52,629,293,000	Mar 31, 2023
PARKMAN HEALTHCARE PARTNERS LLC	1.02%	0.33%	115,000	115,000	100.00%	1,524,900,000	Mar 31, 2023
GMT CAPITAL CORP	9.57%	0.56%	1,083,800	83,800	8.38%	14,371,188,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.49%	0.00%	55,633	55,633	100.00%	748,000	Mar 31, 2023
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	22.39%	0.75%	2,535,723	55,524	2.24%	33,623,687,000	Mar 31, 2023
EVERSEPT PARTNERS, LP	0.40%	0.05%	45,856	45,856	100.00%	608,051,000	Mar 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	0.27%	0.00%	30,100	30,100	100.00%	399,126,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.20%	-	22,367	21,265	1929.67%	301,000,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.16%	-	18,559	18,559	100.00%	249,432,000	Mar 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.	0.06%	0.00%	6,533	6,533	100.00%	12,000	Mar 31, 2023
WOLVERINE ASSET MANAGEMENT LLC	0.04%	0.00%	4,819	4,819	100.00%	63,899,000	Mar 31, 2023
MORGAN STANLEY	0.00%	-	503	503	100.00%	6,670,000	Mar 31, 2023
ATTICUS WEALTH MANAGEMENT, LLC	0.00%	0.00%	166	166	100.00%	2,202,000	Mar 31, 2023
DUPONT CAPITAL MANAGEMENT CORP	-	-	1	-	-	13,000	Mar 31, 2023
ENSIGN PEAK ADVISORS, INC	3.13%	0.01%	355,000	-	-	4,707,300,000	Mar 31, 2023
BVF INC/IL	13.44%	0.75%	1,521,948	-	-	20,454,981,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	35.32%	1.20%	4,000,000	-	-	53,040,000,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	82.48%	9.09%	9,341,551	-	-	125,550,445,000	Mar 31, 2023
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD	17.66%	11.36%	2,000,000	-	-	26,520,000,000	Mar 31, 2023

As of Mar 31 2023, NewAmsterdam Pharma Company's largest institutional buyer is ALYESKA INVESTMENT GROUP, L.P.. The company purchased 289.26K stocks of NAMS, valued at $3.84B.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
JANUS HENDERSON GROUP PLC	-	-	-	-563,119	-100.00%	-	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	-	-	-	-200,000	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-88	-100.00%	-	Mar 31, 2023
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC	73.29%	13.76%	8,300,000	-	-	110,058,000	Mar 31, 2023
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD	17.66%	11.36%	2,000,000	-	-	26,520,000,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	82.48%	9.09%	9,341,551	-	-	125,550,445,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	35.32%	1.20%	4,000,000	-	-	53,040,000,000	Mar 31, 2023
BVF INC/IL	13.44%	0.75%	1,521,948	-	-	20,454,981,000	Mar 31, 2023
ENSIGN PEAK ADVISORS, INC	3.13%	0.01%	355,000	-	-	4,707,300,000	Mar 31, 2023
DUPONT CAPITAL MANAGEMENT CORP	-	-	1	-	-	13,000	Mar 31, 2023
ATTICUS WEALTH MANAGEMENT, LLC	0.00%	0.00%	166	166	100.00%	2,202,000	Mar 31, 2023
MORGAN STANLEY	0.00%	-	503	503	100.00%	6,670,000	Mar 31, 2023
WOLVERINE ASSET MANAGEMENT LLC	0.04%	0.00%	4,819	4,819	100.00%	63,899,000	Mar 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.	0.06%	0.00%	6,533	6,533	100.00%	12,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.16%	-	18,559	18,559	100.00%	249,432,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.20%	-	22,367	21,265	1929.67%	301,000,000	Mar 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	0.27%	0.00%	30,100	30,100	100.00%	399,126,000	Mar 31, 2023
EVERSEPT PARTNERS, LP	0.40%	0.05%	45,856	45,856	100.00%	608,051,000	Mar 31, 2023
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	22.39%	0.75%	2,535,723	55,524	2.24%	33,623,687,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.49%	0.00%	55,633	55,633	100.00%	748,000	Mar 31, 2023

As of Mar 31 2023, NewAmsterdam Pharma Company's biggest institutional seller is JANUS HENDERSON GROUP PLC. The company sold -0.56M shares of NAMS, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ALYESKA INVESTMENT GROUP, L.P.	2.55%	0.03%	289,265	289,265	100.00%	3,835,654,000	Mar 31, 2023
PARKMAN HEALTHCARE PARTNERS LLC	1.02%	0.33%	115,000	115,000	100.00%	1,524,900,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.49%	0.00%	55,633	55,633	100.00%	748,000	Mar 31, 2023
EVERSEPT PARTNERS, LP	0.40%	0.05%	45,856	45,856	100.00%	608,051,000	Mar 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	0.27%	0.00%	30,100	30,100	100.00%	399,126,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.16%	-	18,559	18,559	100.00%	249,432,000	Mar 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.	0.06%	0.00%	6,533	6,533	100.00%	12,000	Mar 31, 2023
WOLVERINE ASSET MANAGEMENT LLC	0.04%	0.00%	4,819	4,819	100.00%	63,899,000	Mar 31, 2023
MORGAN STANLEY	0.00%	-	503	503	100.00%	6,670,000	Mar 31, 2023
ATTICUS WEALTH MANAGEMENT, LLC	0.00%	0.00%	166	166	100.00%	2,202,000	Mar 31, 2023

NewAmsterdam Pharma Company's largest new institutional shareholder by number of shares is ALYESKA INVESTMENT GROUP, L.P., purchased 289.26K shares, valued at $3.84B, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
JANUS HENDERSON GROUP PLC	-	-	-	-563,119	-100.00%	-	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	-	-	-	-200,000	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-88	-100.00%	-	Mar 31, 2023

NewAmsterdam Pharma Company's largest sold out institutional shareholder by shares sold is JANUS HENDERSON GROUP PLC, sold -0.56M shares, valued at -, as of undefined.

NewAmsterdam Pharma Company Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	20	42.86%
31 Dec, 22	14	-

As of 31 Mar 23, 20 institutions are holding NewAmsterdam Pharma Company's shares, representing an increase of 42.86% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	33,353,429	-0.49%
31 Dec, 22	33,516,836	-

NewAmsterdam Pharma Company (NAMS) has 33.35M shares outstanding as of 31 Mar 23, down -0.49% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	100.00%	-
31 Dec, 22	100.00%	-

As of 31 Mar 23, NewAmsterdam Pharma Company is held by 100.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	4	-
31 Dec, 22	-	-

4 institutional shareholders have increased their position in NAMS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	-	-
31 Dec, 22	-	-

- institutional shareholders have reduced their position in NAMS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	20	42.86%	33,353,429	-0.49%	100.00%	-	4	-	-	-
31 Dec, 22	14	-	33,516,836	-	100.00%	-	-	-	-	-

NewAmsterdam Pharma Company Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 24, 2024	Davidson Michael H.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,000	$17.26	$86.31K	204,784
Mar 28, 2024	Topper James N	director	-	P-Purchase	Buy	8,429	$21.50	$181.22K	3,008,429
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	S-Sale	Sell	190,476	$21.50	$4.10M	-
Feb 21, 2024	LANGE LOUIS G	director	-	P-Purchase	Buy	5,000	$19.00	$95.00K	24,878

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 24, 2024	Davidson Michael H.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,000	$17.26	$86.31K	204,784
Mar 28, 2024	Topper James N	director	-	P-Purchase	Buy	8,429	$21.50	$181.22K	3,008,429
Feb 21, 2024	LANGE LOUIS G	director	-	P-Purchase	Buy	5,000	$19.00	$95.00K	24,878

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 03, 2024	JONES WILLIAM A JR	officer	Chief Commercial Officer		Sell	815,598	$10.70	$8.73M	-
May 03, 2024	JONES WILLIAM A JR	officer	Chief Commercial Officer		Sell	130,000	$11.17	$1.45M	-
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	M-Exempt	Sell	201,673	-	-	970,229
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	F-InKind	Sell	11,197	$22.72	$254.40K	190,476
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	S-Sale	Sell	190,476	$21.50	$4.10M	-
Jan 25, 2024	Davidson Michael H.	director, officer	Chief Executive Officer		Sell	100,000	$11.50	$1.15M	-
Jan 25, 2024	LANGE LOUIS G	director	-		Sell	-	-	-	19,878
Jan 25, 2024	LANGE LOUIS G	director	-		Sell	44,619	$11.50	$513.12K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 19, 2024	McKenna Mark C.	director	-	A-Award	Buy	72,500	$18.81	$1.36M	72,500
Jul 19, 2024	Joustra Wouter		-		Buy	-	-	-	-
Jul 19, 2024	McKenna Mark C.		-		Buy	-	-	-	-
Jun 24, 2024	Davidson Michael H.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,000	$17.26	$86.31K	204,784
May 03, 2024	JONES WILLIAM A JR	officer	Chief Commercial Officer		Sell	815,598	$10.70	$8.73M	-
May 03, 2024	JONES WILLIAM A JR	officer	Chief Commercial Officer		Sell	130,000	$11.17	$1.45M	-
Apr 02, 2024	Audet Juliette Berangere	officer	Chief Business Officer	A-Award	Buy	250,000	$21.37	$5.34M	250,000
Mar 28, 2024	Topper James N	director	-	P-Purchase	Buy	8,429	$21.50	$181.22K	3,008,429
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	M-Exempt	Sell	201,673	-	-	970,229
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	M-Exempt	Buy	201,673	-	-	201,673
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	F-InKind	Sell	11,197	$22.72	$254.40K	190,476
Mar 27, 2024	Kastelein Johannes Jacob Pieter	director, officer	Chief Scientific Officer	S-Sale	Sell	190,476	$21.50	$4.10M	-
Feb 21, 2024	LANGE LOUIS G	director	-	P-Purchase	Buy	5,000	$19.00	$95.00K	24,878
Jan 25, 2024	Davidson Michael H.	director, officer	Chief Executive Officer		Sell	100,000	$11.50	$1.15M	-
Jan 25, 2024	LANGE LOUIS G	director	-		Sell	-	-	-	19,878
Jan 25, 2024	LANGE LOUIS G	director	-		Sell	44,619	$11.50	$513.12K	-
Jan 08, 2024	Lewis William	director	-	A-Award	Buy	100,000	$12.01	$1.20M	100,000
Jan 08, 2024	Lewis William		-		Buy	-	-	-	-
Jan 03, 2024	Kooij Louise Frederika	officer	Chief Accounting Officer	A-Award	Buy	150,494	$11.17	$1.68M	150,494
Jan 03, 2024	Kling Douglas F	officer	Chief Operating Officer	A-Award	Buy	323,771	$11.17	$3.62M	323,771

The last insider sell of NewAmsterdam Pharma Company's stock was made by JONES WILLIAM A JR on May 03 2024, selling 815,598 shares at $10.70 per share (valued at $8.73M). The last insider buy of NAMS was made by Davidson Michael H. on Jun 24 2024, buying 5,000 shares at $17.26 per share (worth $86.31K).

NewAmsterdam Pharma Company Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	1	-	-
Q2 2024	2	2	100.00%
Q1 2024	12	3	400.00%
Q4 2023	-	20	-
Q4 2022	-	2	-

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by NewAmsterdam Pharma Company's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	-	-
Q2 2024	1	-	-
Q1 2024	2	1	200.00%
Q4 2023	-	-	-
Q4 2022	-	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of NewAmsterdam Pharma Company's stocks.

NewAmsterdam Pharma Company Peer Ownership

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
CGEM	Cullinan Oncology, Inc.
PRTC	PureTech Health plc
IVA	Inventiva S.A.
MRUS	Merus N.V.
MLYS	Mineralys Therapeutics, Inc.
REPL	Replimune Group, Inc.
JANX	Janux Therapeutics, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
RZLT	Rezolute, Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG
CMPX	Compass Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.

NAMS Ownership FAQ

Who Owns NewAmsterdam Pharma Company?

NewAmsterdam Pharma Company is owned by institutional shareholders (100.00%), insiders (0.26%), and public (-0.26%). The largest institutional shareholder of NewAmsterdam Pharma Company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. (82.48% of total shares) and the top mutual fund owner is (0% of total shares).

Who are the major institutional shareholders of NewAmsterdam Pharma Company?

NewAmsterdam Pharma Company's major institutional shareholders are FRAZIER LIFE SCIENCES MANAGEMENT, L.P., BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). The top five shareholders own together 248.05% of the company's share outstanding.

How many NewAmsterdam Pharma Company shareholders are there?

As of Mar 2023, there are 20 institutional shareholders of NewAmsterdam Pharma Company.

What percentage of NewAmsterdam Pharma Company is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?

FRAZIER LIFE SCIENCES MANAGEMENT, L.P owns 9.34M shares of NewAmsterdam Pharma Company, representing 82.48% of the company's total shares outstanding, valued at $125.55B (as of Mar 2023).

What percentage of NewAmsterdam Pharma Company is owned by BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC?

As of Mar 2023, BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC holds 8.3M shares of NewAmsterdam Pharma Company (NAMS), compromising 73.29% of the company, valued at $110.06M.

What percentage of NewAmsterdam Pharma Company is owned by RA CAPITAL MANAGEMENT, L.P?

RA CAPITAL MANAGEMENT, L.P is the third largest holder of NewAmsterdam Pharma Company. The company owns 4M of the company's shares outstanding (worth $53.04B).